🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

BioMarin to buy rare disease drugmaker Inozyme for $270M biopharmadive.com/news/biomarin-… by Jacob Bell $BMRN $INZY + 177%

Some good news to end the week! For the 3rd year in a row, BioPharma Dive has won SIIA's Neal Award for Best Industry Coverage ... right on the heels of Delilah Alvarado being named a finalist for NIHCM's Trade Journalism Award:

Our Neals submission included three of our most substantial projects from last year: The first, by Jacob Bell, dug into pharma's seemingly renewed confidence in psychiatry drugs and asked questions that, one year later, look even more important: biopharmadive.com/news/psychiatr…

Story on the SiteOne deal from Jacob Bell here: biopharmadive.com/news/lilly-sit… and more on NaV1.8 inhibitors from Jacob in his deep dive on $VRTX's Journavx here: biopharmadive.com/news/pain-drug…

#Biotech funding plummets as Trump policies unnerve investors: Jefferies biopharmadive.com/news/biotech-f… by Jacob Bell

Sorry for the slow responses, I was in Iceland the past week :)

Compass’ big psychedelic study doesn’t impress investors biopharmadive.com/news/compass-p… by Jacob Bell $CMPS - 46% $GHRS $JNJ

Exclusive: FDA's Makary sought rejection of KalVista’s drug in an unusual move by commissioner, sources say My latest — endpoints.news/sources-fda-ch…

Acadia’s ‘very bullish’ sales forecast restores some confidence on Wall Street biopharmadive.com/news/acadia-re… by Jacob Bell $ACAD

Sodium channel blockers for pain: New opportunities after Vertex’s ‘watershed’ moment biopharmadive.com/news/sodium-ch… A deep look at the pipeline of NaV1.8 and NaV1.7 drugs behind Journavx, via Jacob Bell.